Insulin-sensitizing agents: use in pregnancy and as therapy in polycystic ovary syndrome
The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Abstract
Treatment with insulin-sensitizing agents is a relatively recent therapeutic strategy in women with polycystic ovary syndrome (PCOS) and insulin resistance. The key areas addressed in this review include PCOS and the development of type 2 diabetes mellitus and gestational diabetes, as well as the use of insulin-sensitizing agents, particularly metformin, in the management of infertility in obese and non-obese PCOS women. Treatment with metformin in PCOS women undergoing IVF and the use of metformin during gestation will be discussed. The challenge for the health care professional should be the appropriate utilization of pharmacotherapies to improve insulin sensitivity and lower circulating insulin levels resulting in beneficial changes in PCOS phenotype. Further research into the potential role of other insulin-sensitizing agents, such as pioglitazone and rosiglitazone, in the treatment of infertile women with PCOS is needed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873 · cited 1×
“Weightreducing diet and exercise will also contribute to reducing the development of type 2 diabetes mellitus in high risk patients, although these goals are also achieved by pharmacotherapy intervention with metformin (Tuomilehto et al., 2001; Knowler et al., 2002).”
BackgroundFollow-up report on the diagnosis of diabetes mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus* (2003) · Diabetes Care · doi:10.2337/diacare.26.11.3160 · Cited by 3,784
Franks, S. (1995) · New England Journal of Medicine · doi:10.1056/nejm199509283331307 · Cited by 2,463
Buchanan, T. A., & Xiang, A. H. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200524531 · Cited by 2,123
Amenorrhea associated with bilateral polycystic ovaries
Stein, I. F., & Leventhal, M. L. (1935) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(15)30642-6 · Cited by 2,121 · cited 1×
“Stein and Leventhal initially observed the association between amenorrhoea, hirsutism, infertility and polycystic ovaries in the first half of the 20th century (Stein and Leventhal, 1935).”
BackgroundProfound Peripheral Insulin Resistance, Independent of Obesity, in Polycystic Ovary Syndrome
Dunaif, A., Segal, K. R., Futterweit, W., & Dobrjansky, A. (1989) · Diabetes · doi:10.2337/diab.38.9.1165 · Cited by 1,967
A Randomized Trial of a Low-Carbohydrate Diet for Obesity
Foster, G. D., Wyatt, H. R., Hill, J. O., McGuckin, B. G., Brill, C., Mohammed, B. S., Szapary, P. O., Rader, D. J., Edman, J. S., & Klein, S. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022207 · Cited by 1,794 · cited 2×
“There are many diets on offer to consumers but low-energy Mediterranean-style diet (Esposito et al., 2003), high-fibre, whole-grain foods (Liu et al., 2003) and high protein, low carbohydrate diets (Foster et al., 2003) have been shown to be associated with better and more sustained weight loss.”
BackgroundLegro, R. S. (1999) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.1.165 · Cited by 1,743
Esposito, K., Pontillo, A., Di Palo, C., Giugliano, G., Masella, M., Marfella, R., & Giugliano, D. (2003) · JAMA · doi:10.1001/jama.289.14.1799 · Cited by 1,511 · cited 2×
“There are many diets on offer to consumers but low-energy Mediterranean-style diet (Esposito et al., 2003), high-fibre, whole-grain foods (Liu et al.”
BackgroundPrevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome.
Ehrmann, D. A., Barnes, R. B., Rosenfield, R. L., Cavaghan, M. K., & Imperial, J. (1999) · Diabetes Care · doi:10.2337/diacare.22.1.141 · Cited by 1,257 · cited 4×
“5–10%) (Ehrmann et al., 1999), with 5–10-fold increased rate of conversion of impaired glucose tolerance to non-insulin”
BackgroundInfluentialExercise, Glucose Transport, and Insulin Sensitivity
Goodyear, L. J., & Kahn, B. B. (1998) · Annual Review of Medicine · doi:10.1146/annurev.med.49.1.235 · Cited by 1,056 · cited 1×
“The effect of exercise on improving insulin sensitivity independent of weight loss has also been documented (Goodyear and Kahn, 1998).”
BackgroundWild, S., Pierpoint, T., McKeigue, P., & Jacobs, H. (2000) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2000.01000.x · Cited by 970 · cited 1×
“Longitudinal follow-up studies are needed to clarify whether patients with PCOS have an increased risk for atherosclerotic cardiovascular disease, but surrogate markers seem to indicate that the risk of cardiovascular disease is increased (Dahlgren et al., 1992a; Wild et al., 2000; Legro, 2003).”
BackgroundKiddy, D. S., Hamilton‐Fairley, D., Bush, A., Short, F., Anyaoku, V., Reed, M. J., & Franks, S. (1992) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1992.tb02909.x · Cited by 921
Efficacy and Metabolic Effects of Metformin and Troglitazone in Type II Diabetes Mellitus
Inzucchi, S. E., Maggs, D. G., Spollett, G. R., Page, S. L., Rife, F. S., Walton, V., & Shulman, G. I. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803263381303 · Cited by 794 · cited 1×
“When taken together, these results are consistent with an effect of troglitazone on the insulin resistance of the liver and skeletal muscle (Inzucchi et al., 1998).”
ResultLiu, S., Willett, W. C., Manson, J. E., Hu, F. B., Rosner, B., & Colditz, G. (2003) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/78.5.920 · Cited by 787
Metformin in polycystic ovary syndrome: systematic review and meta-analysis
Lord, J. M., Flight, I. H. K., & Norman, R. J. (2003) · BMJ · doi:10.1136/bmj.327.7421.951 · Cited by 786 · cited 13×
“This association achieves significantly better results than clomiphene alone or clomiphene with placebo in terms of induction of ovulation and pregnancy rates (Lord et al., 2003; Kashyap et al., 2004).”
BackgroundMethodInfluentialNestler, J. E., & Jakubowicz, D. J. (1996) · New England Journal of Medicine · doi:10.1056/nejm199608293350902 · Cited by 743
PLYMATE, S. R., MATEJ, L. A., JONES, R. E., & FRIEDL, K. E. (1988) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-67-3-460 · Cited by 693 · cited 1×
“…sex hormone-binding globulin (SHBG) levels, and finally a direct hypothalamic–pituitary effect altering the pattern of circulating gonadotrophins cannot be excluded (Adashi et al., 1981; Poretsky and Kalin, 1987; Plymate et al., 1988; Dunaif, 1997; Nestler et al., 1998a; Arslanian et al., 2002).”
BackgroundClark, A. M., Ledger, W., Galletly, C., Tomlinson, L., Blaney, F., Wang, X., & Norman, R. J. (1995) · Human Reproduction · doi:10.1093/oxfordjournals.humrep.a135772 · Cited by 642
Pasquali, R., Gambineri, A., Biscotti, D., Vicennati, V., Gagliardi, L., Colitta, D., Fiorini, S., Cognigni, G. E., Filicori, M., & Morselli-Labate, A. M. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.8.6738 · Cited by 635 · cited 1×
“Although there is no evidence for an increased difficulty to reduce weight and to maintain fat loss in obese women with PCOS compared with non-obese women (Pasquali et al., 2000; Moran and Norman, 2004; Norman et al., 2004), weight management interventions are frequently unsuccessful.”
BackgroundPrevalence and predictors of dyslipidemia in women with polycystic ovary syndrome
Legro, R. S., Kunselman, A. R., & Dunaif, A. (2001) · The American Journal of Medicine · doi:10.1016/s0002-9343(01)00948-2 · Cited by 622 · cited 2×
“…insulin resistance of PCOS have been also associated with alterations of circulating lipid and lipoprotein levels with significant increase of low-density lipoprotein cholesterol, total cholesterol and triglyceride levels and decrease of high-density lipoprotein cholesterol (Legro et al., 2001).”
BackgroundDunaif, A., Xia, J., Book, C. B., Schenker, E., & Tang, Z. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118126 · Cited by 561 · cited 2×
“…that insulin resistance may be present in both obese and non-obese patients with PCOS (Chang et al., 1983; Dunaif, 1997), although insulin resistance of PCOS appears to be aggravated by the presence of obesity (Lobo et al., 1982; Ciaraldi et al., 1992; Dunaif et al., 1995; Nestler et al., 2002).”
BackgroundMoran, L. J., Noakes, M., Clifton, P. M., Tomlinson, L., & Norman, R. J. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-020815 · Cited by 530
Mortality of Women with Polycystic Ovary Syndrome at Long-term Follow-up
Pierpoint, T., McKeigue, P. M., Isaacs, A. J., Wild, S. H., & Jacobs, H. S. (1998) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(98)00035-3 · Cited by 504 · cited 2×
“records and followed for an average of 30 years, markedly higher than average mortality from circulatory disease was not observed, although the condition is strongly associated with diabetes, lipid abnormalities and other cardiovascular risk factors (Pierpoint et al., 1998).”
BackgroundPolycystic ovary syndrome and cardiovascular disease: a premature association?
Legro, R. S. (2003) · Endocrine Reviews · doi:10.1210/er.2003-0004 · Cited by 466 · cited 1×
“Longitudinal follow-up studies are needed to clarify whether patients with PCOS have an increased risk for atherosclerotic cardiovascular disease, but surrogate markers seem to indicate that the risk of cardiovascular disease is increased (Dahlgren et al., 1992a; Wild et al., 2000; Legro, 2003).”
BackgroundHolte, J., Bergh, T., Berne, C., Wide, L., & Lithell, H. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.80.9.7673399 · Cited by 435
Insulin resistance, polycystic ovary syndrome, and type 2 diabetes mellitus
Ovalle, F., & Azziz, R. (2002) · Fertility and Sterility · doi:10.1016/s0015-0282(02)03111-4 · Cited by 428 · cited 5×
“However, it seems that the WHO criteria are more adequate for the diagnosis of diabetes in women with PCOS (Ovalle and Azziz, 2002).”
BackgroundInfluentialADASHI, E. Y., HSUEH, A. J. W., & YEN, S. S. C. (1981) · Endocrinology · doi:10.1210/endo-108-4-1441 · Cited by 366 · cited 1×
“…sex hormone-binding globulin (SHBG) levels, and finally a direct hypothalamic–pituitary effect altering the pattern of circulating gonadotrophins cannot be excluded (Adashi et al., 1981; Poretsky and Kalin, 1987; Plymate et al., 1988; Dunaif, 1997; Nestler et al., 1998a; Arslanian et al., 2002).”
BackgroundLong or Highly Irregular Menstrual Cycles as a Marker for Risk of Type 2 Diabetes Mellitus
Solomon, C. G. (2001) · JAMA · doi:10.1001/jama.286.19.2421 · Cited by 362 · cited 2×
“mellitus in women with PCOS may be independent of obesity (Solomon et al., 2001).”
BackgroundNorman, R. J., Masters, L., Milner, C. R., Wang, J. X., & Davies, M. J. (2001) · Human Reproduction · doi:10.1093/humrep/16.9.1995 · Cited by 341 · cited 3×
“…particularly those with a high BMI, should be reviewed regularly with respect to impaired glucose tolerance, as the rate of conversion from impaired glucose tolerance to non-insulin dependent diabetes mellitus is substantial (Ehrmann et al., 1999; Norman et al., 2001; Gambineri et al., 2004b).”
BackgroundInfluentialNESTLER, J. E., BARLASCINI, C. O., MATT, D. W., STEINGOLD, K. A., PLYMATE, S. R., CLORE, J. N., & BLACKARD, W. G. (1989) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-68-6-1027 · Cited by 338 · cited 1×
“These initial experiences were limited to short-term studies aimed at investigating the physiopathological mechanisms of suppressing serum insulin levels using diazoxide and somatostatin analogues (Nestler et al., 1989).”
BackgroundCellular mechanisms of insulin resistance in polycystic ovarian syndrome
Ciaraldi, T. P. (1992) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.75.2.577 · Cited by 336 · cited 2×
“…that insulin resistance may be present in both obese and non-obese patients with PCOS (Chang et al., 1983; Dunaif, 1997), although insulin resistance of PCOS appears to be aggravated by the presence of obesity (Lobo et al., 1982; Ciaraldi et al., 1992; Dunaif et al., 1995; Nestler et al., 2002).”
BackgroundBaillargeon, J.-P., Jakubowicz, D. J., Iuorno, M. J., Jakubowicz, S., & Nestler, J. E. (2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2004.02.127 · Cited by 300 · cited 3×
“Rosiglitazone has been found to increase ovulatory frequency and ameliorate hyperandrogenemia, even in non-obese women with PCOS who appear to have normal insulin sensitivity (Baillargeon et al., 2004).”
BackgroundInfluentialArslanian, S. A., Lewy, V., Danadian, K., & Saad, R. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.4.8398 · Cited by 272 · cited 1×
“…sex hormone-binding globulin (SHBG) levels, and finally a direct hypothalamic–pituitary effect altering the pattern of circulating gonadotrophins cannot be excluded (Adashi et al., 1981; Poretsky and Kalin, 1987; Plymate et al., 1988; Dunaif, 1997; Nestler et al., 1998a; Arslanian et al., 2002).”
BackgroundMusso, C., Cochran, E., Moran, S. A., Skarulis, M. C., Oral, E. A., Taylor, S., & Gorden, P. (2004) · Medicine · doi:10.1097/01.md.0000133625.73570.54 · Cited by 264 · cited 1×
“The insulin receptor and genetics of PCOS are complex areas that are extensively being investigated (Musso et al., 2004).”
BackgroundCostello, M. F., & Eden, J. A. (2003) · Fertility and Sterility · doi:10.1016/s0015-0282(02)04554-5 · Cited by 224 · cited 7×
“Metformin monotherapy has not been useful in decreasing BMI (Costello and Eden, 2003).”
BackgroundInfluentialGambineri, A., Pelusi, C., Genghini, S., Morselli‐Labate, A. M., Cacciari, M., Pagotto, U., & Pasquali, R. (2004) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2004.01973.x · Cited by 216 · cited 2×
“…particularly those with a high BMI, should be reviewed regularly with respect to impaired glucose tolerance, as the rate of conversion from impaired glucose tolerance to non-insulin dependent diabetes mellitus is substantial (Ehrmann et al., 1999; Norman et al., 2001; Gambineri et al., 2004b).”
BackgroundPolycystic ovaries and recurrent miscarriage—a reappraisal
Rai, R., Backos, M., Rushworth, F., & Regan, L. (2000) · Human Reproduction · doi:10.1093/humrep/15.3.612 · Cited by 215 · cited 2×
“On the other hand, neither an elevated serum LH hormone concentration (.10 IU/l) nor an elevated serum testosterone concentration (.3 nmol/l) was associated with an increased miscarriage rate (Rai et al., 2000).”
BackgroundGiugliano, D., De Rosa, N., Di Maro, G., Marfella, R., Acampora, R., Buoninconti, R., & D'Onofrio, F. (1993) · Diabetes Care · doi:10.2337/diacare.16.10.1387 · Cited by 206 · cited 2×
“Metformin has beneficial effects on serum lipid profiles in obese(Giugliano et al., 1993) and lean patients with non-insulin dependent diabetes mellitus, in other patients with type 2 diabetes and in patients with concomitant type 2 diabetes, hypertension and/or hyperlipidaemia (Landin et al.,…”
BackgroundObstetric outcome in women with polycystic ovarian syndrome
Mikola, M. (2001) · Human Reproduction · doi:10.1093/humrep/16.2.226 · Cited by 206
Gestational Diabetes Mellitus: A Survey of Perinatal Complications in the 1980s
Hod, M., Merlob, P., Friedman, S., Schoenfeld, A., & Ovadia, J. (1991) · Diabetes · doi:10.2337/diab.40.2.s74 · Cited by 188
KIDDY, D. S., HAMILTON‐FAIRLEY, D., SEPPÄLÄ, M., KOISTINEN, R., JAMES, V. H. T., REED, M. J., & FRANKS, S. (1989) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1989.tb01297.x · Cited by 182
Acién, P., Quereda, F., Matallı́n, P., Villarroya, E., López-Fernández, J. A., Acién, M., Mauri, M., & Alfayate, R. (1999) · Fertility and Sterility · doi:10.1016/s0015-0282(99)00184-3 · Cited by 170 · cited 4×
“Insulin resistance is present in less than 10% of non-obese patients with PCOS (Meirow et al., 1995; Acién et al., 1999), but the prevalence largely increases in obese or overweight women with android fat distribution, or sedentary lifestyle and predominance of dietary saturated fat content, which…”
BackgroundInfluentialIncreased prevalence of insulin resistance in women with a history of recurrent pregnancy loss
Craig, L. B., Ke, R. W., & Kutteh, W. H. (2002) · Fertility and Sterility · doi:10.1016/s0015-0282(02)03247-8 · Cited by 166 · cited 1×
“It has been also shown that women with recurrent pregnancy loss have a significantly increased prevalence of insulin resistance when compared with matched fertile controls (Craig et al., 2002; Jakubowicz et al., 2004).”
ResultSensitization to Insulin Induces Ovulation in Nonobese Adolescents with Anovulatory Hyperandrogenism
Ibáñez, L., Valls, C., Ferrer, A., Marcos, M. V., Rodriguez-Hierro, F., & de Zegher, F. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.8.7756 · Cited by 162 · cited 1×
“…have been shown to decrease ovarian and adrenal cytochrome P450c17a, ameliorating hyperandrogenism, decreasing the concentration of androgenic metabolites and restoring ovulatory function (Nestler and Jakubowicz, 1996, 1997; De Leo et al., 1999; Azziz et al., 2001; Ibáñez et al., 2001).”
BackgroundArlt, W., Auchus, R. J., & Miller, W. L. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m100040200 · Cited by 157 · cited 2×
“synthesis indirectly, probably by lowering circulating insulin concentrations (Arlt et al., 2001).”
BackgroundAndersen, P., Seljeflot, I., Abdelnoor, M., Arnesen, H., Dale, P. O., Løvik, A., & Birkeland, K. (1995) · Metabolism · doi:10.1016/0026-0495(95)90118-3 · Cited by 156
Metformin, pre-eclampsia, and pregnancy outcomes in women with polycystic ovary syndrome
Glueck, C. J., Bornovali, S., Pranikoff, J., Goldenberg, N., Dharashivkar, S., & Wang, P. (2004) · Diabetic Medicine · doi:10.1111/j.1464-5491.2004.01251.x · Cited by 115
Ibáñez, L., Ong, K., Ferrer, A., Amin, R., Dunger, D., & de Zegher, F. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-022002 · Cited by 100 · cited 2×
“…and insulin resistance is associated with an atherogenic lipid profile, alterations of adipocytokines (mostly at the expense of interleukin-6) and decreased lean body mass (Kirchengast and Huber, 2001; Pirwany et al., 2001; Ducluzeau et al., 2003; Ibáñez et al., 2003; Ibañez and Zegher, 2005).”
BackgroundOvulation and pregnancy rates with clomiphene citrate
GORLITSKY, G. A., KASE, N. G., & SPEROFF, L. (1978) · Obstetrics & Gynecology · doi:10.1097/00006250-197803000-00002 · Cited by 99 · cited 1×
“Clomiphene citrate has been shown to be effective for induction of ovulation in patients with PCOS, although an ovulation rate of 80% is clearly in contrast to pregnancy rates of 30–40% (Gorlitsky et al., 1978; Lunenfeld et al., 1991; Kousta et al., 1997).”
BackgroundHamilton‐Fairley, D., Kiddy, D., Anyaoku, V., Koistinen, R., Seppälä, M., & Franks, S. (1993) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1993.tb02378.x · Cited by 75 · cited 2×
“, 2003) followed by correction of hyperandrogenism and restoring reproductive and metabolic physiology (Kiddy et al., 1989; Pasquali et al., 1989; Hamilton-Fairley et al., 1993; Jakubowicz and Nestler, 1997; Crosignani et al., 2003).”
Background
Cited by
Palomba, S., Falbo, A., Zullo, F., & Orio, F. (2009) · Endocrine Reviews · doi:10.1210/er.2008-0030 · Cited by 426
Costello, M. F., Shrestha, B., Eden, J., Johnson, N., & Moran, L. J. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005552.pub2 · Cited by 197
Diet and nutrition in polycystic ovary syndrome (PCOS): Pointers for nutritional management
Farshchi, H., Rane, A., Love, A., & Kennedy, R. L. (2007) · Journal of Obstetrics and Gynaecology · doi:10.1080/01443610701667338 · Cited by 87
“Metformin is extensively used in patients with PCOS, not only because of its effects on glucose homeostasis, but also because by decreasing insulin resistance it leads to favourable changes in androgens and gonadotrophins (Checa et al. 2005).”
BackgroundZhuo, Z., Wang, A., & Yu, H. (2014) · Journal of Diabetes Research · doi:10.1155/2014/381231 · Cited by 55
“In summary, according to the results of our meta-analysis, strictly, metformin did not significantly effect on GDM with PCOS, though more multicenters RCTs still need to be investigated.”
Tagliaferri, V., Romualdi, D., Immediata, V., De Cicco, S., Di Florio, C., Lanzone, A., & Guido, M. (2017) · Clinical Endocrinology · doi:10.1111/cen.13304 · Cited by 40
Metadata
- Authors
- Checa, M. A., Requena, A., Salvador, C., Tur, R., Callejo, J., Espinós, J. J., Fábregues, F., Herrero, J., & (Reproductive Endocrinology Interest Group of the Spanish Society of Fertility)
- Venue
- Human Reproduction Update
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-05-05
- Volume
- 11
- Issue
- 4
- Pages
- 375-390
- ISSN
- 1355-4786 (ISSN-L)
- 1460-2369
- OpenAlex
- W2154575384
- Cited by
- 60
- References
- 53
- FWCI
- 8.14
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.